Biotech Values

[zipjet]

But not good for final approval - at least not without additional data.

In prostate cancer that has metathesized "evidence of bone scan resolution (partial or complete)" occurred in 19 out of 20 patients treated with XL184. Bone/skeletal failure reductions should extend life, IMO since that is the main cause of death.

12 out of 20 had reduced pain.

Is that NOT good enough for approval?



ij